Profile data is unavailable for this security.
About the company
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-29.76m
- Incorporated2011
- Employees17.00
- LocationTempest Therapeutics Inc2000 SIERRA POINT PARKWAY, SUITE 400BRISBANE 94005United StatesUSA
- Phone+1 (415) 798-8589
- Fax+1 (302) 655-5049
- Websitehttps://www.tempesttx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protara Therapeutics Inc | 0.00 | -42.47m | 43.24m | 26.00 | -- | 0.4111 | -- | -- | -3.74 | -3.74 | 0.00 | 5.11 | 0.00 | -- | -- | 0.00 | -48.67 | -37.02 | -52.23 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
| Dyadic International Inc | 2.26m | -7.85m | 43.27m | 7.00 | -- | 9.57 | -- | 19.19 | -0.2724 | -0.2724 | 0.0783 | 0.1547 | 0.1769 | -- | 4.51 | 322,197.20 | -61.58 | -36.82 | -73.50 | -39.85 | 38.24 | 22.47 | -348.00 | -410.16 | -- | -- | 0.5634 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
| Inotiv Inc | 552.74m | -71.29m | 43.63m | 1.96k | -- | 0.2101 | -- | 0.0789 | -2.77 | -2.77 | 21.44 | 8.00 | 0.6565 | 7.18 | 7.91 | 282,733.50 | -8.58 | -23.84 | -13.63 | -29.26 | 28.76 | 29.31 | -13.07 | -33.24 | 0.2744 | -0.1734 | 0.6476 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| NextCure Inc | 0.00 | -63.73m | 43.92m | 82.00 | -- | 0.4423 | -- | -- | -2.29 | -2.29 | 0.00 | 3.55 | 0.00 | -- | -- | 0.00 | -45.05 | -22.59 | -47.72 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| Calcimedica Inc | 0.00 | -14.94m | 45.79m | 14.00 | -- | 2.65 | -- | -- | -2.64 | -2.64 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -48.34 | -63.99 | -66.59 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
| Lantern Pharma Inc | 0.00 | -17.53m | 46.16m | 21.00 | -- | 1.29 | -- | -- | -1.62 | -1.62 | 0.00 | 3.32 | 0.00 | -- | -- | 0.00 | -36.82 | -28.83 | -39.63 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
| Marker Therapeutics Inc | 3.32m | -12.21m | 46.29m | 8.00 | -- | 3.92 | -- | 13.94 | -1.38 | -0.636 | 0.3751 | 1.32 | 0.158 | -- | 1.69 | 415,107.50 | -58.12 | -53.74 | -70.75 | -62.25 | -- | -- | -367.79 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -29.76m | 46.88m | 17.00 | -- | 2.27 | -- | -- | -1.76 | -1.76 | 0.00 | 0.9287 | 0.00 | -- | -- | 0.00 | -72.84 | -57.10 | -93.72 | -71.20 | -- | -- | -- | -- | -- | -141.39 | 0.3394 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Conduit Pharmaceuticals Inc | 0.00 | -2.42m | 47.26m | 7.00 | -- | -- | -- | -- | -0.0339 | -0.0339 | 0.00 | -0.042 | 0.00 | -- | -- | 0.00 | -97.97 | -- | -- | -- | -- | -- | -- | -- | -- | -25.68 | -- | -- | -- | -- | 89.05 | -- | -- | -- |
| LAVA Therapeutics NV | 12.54m | -28.59m | 47.32m | 37.00 | -- | 0.934 | -- | 3.77 | -1.07 | -1.07 | 0.4668 | 1.93 | 0.107 | -- | 9.09 | 338,837.80 | -24.40 | -- | -28.91 | -- | 79.64 | -- | -228.02 | -- | -- | -- | 0.108 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Cue Biopharma Inc | 7.02m | -49.97m | 47.67m | 53.00 | -- | 1.59 | -- | 6.79 | -1.07 | -1.07 | 0.1495 | 0.6175 | 0.1035 | -- | 8.80 | 132,452.80 | -73.69 | -57.45 | -96.35 | -68.41 | -- | -- | -711.84 | -810.87 | -- | -- | 0.1935 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Aerovate Therapeutics Inc | 0.00 | -82.19m | 48.69m | 51.00 | -- | 0.5187 | -- | -- | -3.03 | -3.03 | 0.00 | 3.26 | 0.00 | -- | -- | 0.00 | -71.09 | -- | -80.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
| Arca Biopharma Inc | 0.00 | -6.00m | 50.34m | 4.00 | -- | 1.43 | -- | -- | -0.4155 | -0.4155 | 0.00 | 2.42 | 0.00 | -- | -- | 0.00 | -15.24 | -27.78 | -15.81 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
| Reneo Pharmaceuticals Inc | 0.00 | -70.71m | 50.47m | 8.00 | -- | 0.6212 | -- | -- | -2.17 | -2.17 | 0.00 | 2.43 | 0.00 | -- | -- | 0.00 | -77.06 | -- | -83.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Mural Oncology PLC | 0.00 | -191.90m | 50.77m | 117.00 | -- | 0.2161 | -- | -- | -11.49 | -11.49 | 0.00 | 13.88 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
Data as of Jul 05 2024. Currency figures normalised to Tempest Therapeutics Inc's reporting currency: US Dollar USD
5.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 508.20k | 2.29% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 174.01k | 0.78% |
| Geode Capital Management LLCas of 31 Mar 2024 | 132.08k | 0.60% |
| FIL Investment Advisors (UK) Ltd.as of 31 Mar 2024 | 129.58k | 0.58% |
| Ikarian Capital LLCas of 31 Mar 2024 | 105.60k | 0.48% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 43.02k | 0.19% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 41.49k | 0.19% |
| Simplex Trading LLCas of 31 Mar 2024 | 37.82k | 0.17% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 34.18k | 0.15% |
| Virtu Americas LLCas of 31 Mar 2024 | 28.57k | 0.13% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
